An extensive review about Transfersomes

Tarun Parashar[1], Manish Kumar[1], Pranjal Shaw[1], Rohit Kumar[1] &

Soniya rani[1]

[1]*Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, INDIA*

Corresponding Author Email ID: soniyaranio487@gmail.com

Abstract

Transferosomes administer specialized transdermal medicines. Phosphatidylcholine and an activator are present at the liposome's edge. Phospholipid vesicles are another transdermal drug carrier. The skin is the biggest organ, weighing three kilograms and measuring 1.5 to 2.0 square meters. Ineffective drug carriers include liposomes, noisomes, and microemulsions. Transfersomes are a new type of composite body designed using the rational membrane design idea. Pores in the stratum corneum are smaller than normal, allowing Transfersomes to enter the skin. This is because it may be misspelt. In the laboratory, vascular vesicles can be measured for size, entrapment efficiency, distortion, and density. Osmotic gradient enters through intracellular or transcellular pathways. Besides biocompatibility and biodegradability, transferosomes have other benefits. Among the drawbacks are oxidative degradation and expensive prices. The transfersomes were made by rotary evaporation sonication and then dissolved in water. Lipids include phospholipids, surfactants, and medications. Size distribution and zeta potential can be utilized to assess transferosome performance. Shape, density, and encapsulation efficiency appraising a person's ability to solve a problem density and charge on the surface Drug release from skin in vitro Transferosomes provide for controlled release and transdermal vaccination.

Keywords: *Transfersomes, Transdermal drug delivery system, Modified Transfersomes, Entrapment*

1. Introduction

Ionic amphiphiles like dicetylphosphate and stearyl amine can help niosomes stay stable and operate better . To comparison, these nanoparticles outperform liposomes on chemical stability, bioavailability, entrapment efficiency, and cost. Skin issues plague millions of individuals daily. 30–70% of the world's population has a dermatological disorder [1]. Skin infections are commonly caused by bacteria, fungi, viruses, and inflammation [2]. They have a big psychological influence on those with skin issues. Despite substantial breakthroughs in the profession, dermatologists are still unable to cure many infectious skin diseases. The skin barrier, patient health, and pathogen type all have a role . Invasion of T cells and cytokines cause chronic skin disease . Surface skin illnesses require rapid diagnosis and tailored topical treatment. Notably: medicine delivery device and distribution method.

This review examines recent advances in treating skin problems with lipid-based nanosystems. The most studied lipid-based nanocarriers for cutaneous drug administration are nanovesicular carriers, nanoparticulate carriers, microemulsions, and nanoemulsions. They are created for local use to show the present state of development.

Diverse clinical scenarios are presently exploring transfersome-based formulations. Phase III clinical trials evaluated the safety and efficacy of ketoprofen transfersomes for knee osteoarthritis. A drug enclosed in transfersomal carriers outperformed a placebo in relieving knee osteoarthritis pain. The nomenclature, underlying concept, preparation and characterisation methods, and factors defining properties of the first generation of elastic vesicles will be useful to researchers (transfersomes). Transdermal medication delivery techniques, formulations, and characterization methods are examined in this review[3].

1.2 TRANSFERSOMES:

Due to concerns with oral drug delivery techniques, transdermal drug delivery is currently increasingly important. Microneedles, nanoneedles, sonophoresis, and vesicles including liposomes, ethosomes, transfersomes, and cetosomes have all been utilised to increase transdermal delivery[4]. Transfersomes aid in the delivery of active substances. Phospholipids and water make up this carrier system. Gregor Cevc established the notion of transfersomes in 1991. Transferosomes are resilient, elastic, and highly adaptable. The hydrated core is surrounded by a thin layer of lipids in an ultra-deformable complex. The vesicle is self-optimizing and self-regulating due to the bilayer composition and local composition interdependency. This property allows the vesicle to bypass transport barriers and deliver active substances in a targeted and noninvasive manner.



Fig: 1 Structure of Transfersomes

A trademark of IDEA AG. "soma" means "carrying body" in Latin and Greek. Transferred means to move; "soma" signifies body[5]. An artificial vesicle mimics a cell's exocytosis mechanism to deliver medications precisely. Water causes lipid bilayers to form, and lipid vesicles are the outcome of carrier aggregation. This bilayer has an amphipathic molecule (such as a phospholipid). A biocompatible surfactant is commonly used to soften bilayers and increase permeability[6]. Change the concentration of each bilayer component in this vesicle to change its form if you're anxious or tense. Liposomes are stiffer than transfersomes. They are more flexible than liposomes. The bilayer distortion improves water absorption and retention.

Table: 1 Advantage And Disadvantage of Transferosome [7]

Method	Advantages	Disadvantages
Penetration enhancers	Increase penetration through skin and give local and systemic effects	Skin irritation immunogenicity, only for low molecular weight drugs
Lontophoresis	Increase penetration	Only for charge drug
Liposomes	Phospholipid vesicle	Transfer efficiency low
Proliposomes	More stable than liposomes	Less penetration, cause aggregation
Niosomes	Non-ionic surfactant	Less skin penetration easy handling
Promiosomes	Will convert into iosomein situ, stable	Not rich upto deeper skin layer

1.3 Mechanism of Action

Transfersomes are a special type of liposome. A buffering agent, alcohol, and phospholipids comprise transfersomes[8]. Transfersomes can enter cells via intracellular lipid bilayer routes. Transfersomes can easily penetrate intact vesicles due to their great deformability and hydrophilic/hydrophobic properties[9]. It can thus penetrate deeper into the skin than liposomal drug delivery. Transfersomes constrict the skin's intracellular sealing lipid, limiting penetration. Surface-active components in the correct proportions can make transfersome membranes more adaptive. The skin's barrier function prevents transdermal drug distribution[10]. Transfersomes' ability to cross transport barriers may allow for non-invasive targeted drug administration and ongoing therapeutic chemical release. Low and high molecular weight medicines are suitable for transdermal delivery. Entrapment efficiency can reach 90%[11].



Fig: 2 M.O.A OF TRANSFERSOMES

1.4 Composition of Transfersomes

- They're equipped to tolerate medications of varied solubility thanks to existence of hydrophillic and hydrophobic moieties in its infrastructure[12].
- High deformability of this approach provides improved penetration of intact vesicles. Low and high relative molecular mass medications can be transported by them, such as analgesics, anaesthetics and corticosteroids, steroid hormones, anticancer agents, insulin, and albumins.

- These nanoparticles can transport medications with a wide range of molecular masses[13].
- They're biocompatible and biodegradable as they're made up of natural phospholipids almost like liposomes[14].
- Entrapment effectiveness of transfersomes is extremely high. When it comes to hydrophillic medications, the maximum amount is around 90%.
- Proteins and peptides do this by preventing the encapsulated medicine from being broken down by the body's metabolism.

Table: 2 Various Drugs used with Transfersomal drug delivery system [15]

Drug	Category	Therapeutic activity
Dexamethasone	Corticosteroid Drug	Anti-edema activity
Diclofenac	NSAID agent	Formulation optimization
Tacrolimus	Immunosuppressive	Atopic dermatitis
Pentoxifyllin	Xanthine Derivative	Chronic occlusive arterial disease.
Eprosartan Mesylate	Angiotensin receptor blockers (ARBs)	Management of Hypertension
Ciprofloxacin	Quinolone Antibiotic	Treatment of otitis media
Timolol maleate	Nonselective β-adrenergic blocker	Management of Hypertension
Ketoconazole	Azole antifungal	Antimicrobial activity

1.5 Factor Affecting Composition of Transfersomes

- The phospholipid ratio must be optimised for vesicle size, encapsulation efficiency, and drug penetration. The redesigned structure reduced EE[16].

- Solvents are chosen for their solubility and compatibility (such as ethanol, methanol). The formulation's solvents may improve medication flow by increasing membrane penetration[17].

- Edge activators influence vesicle deformability and entrapment efficiency (such as Tween 80, Span 80, and Sodium deoxycholate). The vesicles shrink with surfactant concentration, hydrophilicity, chain length length, and HLB (HLB). Surfactant concentrations above 15% reduce vesicle size.

- Wet or saline-phosphate buffer can be used for hydration. The formulation's pH should match the product's characteristics, biological applications, and distribution technique for best outcomes. Uniformly unionised medications can only enter cells via the intracellular channel of transfersomes, which mirrors the cell membrane's phospholipid bilayer. The optimal pH hydration media traps and penetrates the drug effectively.

1.6 Application of Transfersomes

- In order to deliver high molecular weight drugs to the skin, transfersome is used. The most common, but most painful, insulin injection is subcutaneous. Insulin in a transfersome replaces typical insulin administration (transfersulin). The therapeutic impact of transferulin on healthy skin lasts 90-180 minutes depending on carrier makeup.
- Transfersomes with steroids mask delivery issues. Transfersome encapsulation makes corticosteroid injections into the skin safer and more precise. Transfersomes inhibit corticosteroid biological action [18].
- Most NSAIDs cause GI side effects. For transdermal dispersion, we can use a transfersome[95]. No studies on diclofenac or ketoprofen have been done. Swissmedic licenced and will market a transfersome ketoprofen known as "Diractin" in 2007. IDEA AG claims it is also used to develop novel drugs [19].
- As a result, it changes the way we treat malignancies like skin cancer. Researchers used transfersomes to deliver methotrexate transdermally[20].

Conclusion

A simple external jolt can cause transfersomes to change form. These deformable particles can pass through biological barriers like skin. In a controlled environment in a lab. Transfersomes can flow through 100 mm holes as efficiently as water. They can administer up to 100mg of medication per hour (up to 100mg cm2h-1) via the skin (up to 100mg cm2h-1). Although stratum corneum penetration is a rate limiting step, it is unable to carry bigger molecules. Thus, bacterial transfersome-like vesicular systems Pores allow elastin vesicles to enter. Its recipe outperforms others in efficacy and security. This delivery technology allows for controlled medication release. So standard techniques' flaws can be avoided. Ultra-deformable vesicles may solve transport

issues. Due to their lack of rigidity, these vesicles can carry large molecules. They use a variety of strategies to deliver pharmaceuticals. In simulated systems with pores as small as 100 mm, transfersomes are virtually as efficient as water. They can administer up to 100mg of medication per hour (up to 100mg cm2h-1) via the skin (up to 100mg cm2h-1). Unwanted physicochemical features, as well as drugs with a faster and more precise effect, can all be supplied this way.

REFERENCE

1. Pandey Shivanand, Goyani Manish, Devmurari Viral, Fakir Jarina. Transferosomes: A Novel Approach for Transdermal Drug Delivery. Der Pharmacia Lettre 2009; 1(2):143- 150.
2. Porfire AS, Parvu AE, Daicoviciu D, Leucuta SE. Evaluation of anti-inflammatory Activity of liposome encapsulated Superoxide dismutase in rats Peritonitis. Farmacia 2009; 57(4):412-423
3. Wearner RR, Myers MC, Taylor DA. Electron Probe Analysis of Human Skin: Determination of the Water Concentration Profile. J Investigative Dermatoogy 1988; 90:218-224
4. Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics. Int J Pharma 2006; 68:5758.
5. Kumar, R., & Dubey, A. PHYTOCHEMICAL INVESTICATION AND HEPTOPROTECTIVE EVALUTION ACACIA RUBICA EXTRACT ISONIZED AND PARACETAMOL INDUSED ANIMAL TOXICITY. *Turkish Journal of Physiotherapy and Rehabilitation*, *32*, 3..
6. Patel R., Singh S.K., Singh. S, Sheth N.R., Gendle R. “Development and Characterization of Curcumim Loaded Transfersome for Transdermal Delivery” journal of pharmaceutical research and science, 2009; 1(4): 71-80.
7. Gupta A., Aggarawal G., Singla S., Rora R., A, “Transfersomes: A Novel Vesicular Carrier for Enhanced Transdermal Delivery of Sertraline: Development, Characterization and performance Evaluation,” Sci Pharm, 2012; 80: 1061-1080.
8. Kavitha K, Bharath N, Mani T T., “Physical Permeation Enhancers for Transdermal Drug Delivery “Research of Journal of pharmaceutical, Biological and Chemical sciences, October-December 2011; 2(4): 66.
9. Dave V., Kumar D., Lewis S., Paliwal S., “Ethosome for Enhanced Transdermal Drug Delivery of Aceclofenac” International Journal of Drug Delivery, 2010; 2: 81-92. 15. Kumar R., Philip A. “Modified Transdermal Technologies: Breaking the Barriers of Drug Permeation via the Skin” Page no.1-15.
10. Modi CD, Bharadia PD. Transfersomes: A newdominants for transdermal drug delivery. Am J PharmTech Res 2012; 2:71-91.

11. Bhatt S, Nimkar S, Clinical Research in Ayurveda: A Preliminary Review of 225 Papers Published In Indian Ayurveda Journals, Journal of Dental and Medical Sciences, 2015; 14 (2):43-50.
12. Merdan VM, Alhaique F, and Touitou E, Vesicular carriers for topical delivery, Acta Techno. Legis Medicament, 1998, 12, 1- 6.
13. Khurana B, Bajaj R, Girotra L, Vesosomal Drug Delivery In Liposomes: A Review, International Journal of Pharmacy, 2012; 2(4):768-776.
14. Chandrika MV, Manasa GS, Mounica1 PL, Varsha PH, Bhavyasri P, Sphingosomes: A Novel Approach for Vesicular DruDelivery System, American Journal of PharmTechResearch, 2016; 6 (2):119-130.
15. Pople PV, Singh KK, Nanoparticles: Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A, American Association of Pharmaceutical Scientists PharmSci Tech, 2006; 7, 91
16. Ashish Y. Pawar, Jadhav KR, Chaudhari LH, Transfersome: A Novel Technique Which Improves Transdermal Permeability, Asian Journal of Pharmaceutics, 2016 (Suppl), 10; (4):S425- S436
17. Jain NK. Advances in Controlled and Novel Drug Delivery. Ed. New Delhi: CBS Publishers and Distributers; 2001. P. 426- 451.
18. Yoshioka T, Sternberg BF, Lorence AT, Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85), International Journal of Pharmaceutics, 1994; 105:1-6
19. Ghada M, Holayel SM, Mortada ND, Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery, International Journal of Pharmaceutics, 2010; 397:164–172.
20. Walve JR, Bakliwal SR, Rane BR, Pawar SP, Transfersomes: A Surrogated Carrier for Transdermal Drug Delivery System, International Journal of Applied Biology and Pharmaceutical Technology, 2011; 2 (1):204-213.
21. Singh S, Verma D, Aamir M, et al. Development and optimization of ketoconazole loaded nano-transfersomal gel for vaginal delivery using Box-Behnken design:In vitro, ex vivo characterization and antimicrobial evaluation, Journal of Drug Delivery Science and Technology, 2017; 39:95-10.
22. Chaudhary H, Kohli K, Kumar V, Nano-transfersomes as a novel carrier for transdermal delivery, International Journal of Pharmaceutics, 2013; 454(1):367-380
23. Bavarsad N, Bazzaz BSF, Khamesipour A, Jaafari MR, Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice, Acta Tropica, 2012; 124(1):33-41.
24. Ramezani V, Honarvar M, Seyedabadi M, Karimollah A, Hashemi M, Formulation and optimization of transfersomes containing minoxidil and caffeine, Journal of Drug Delivery Science and Technology, 2018; 44:129-135.

25. Wang J, Wei Y, Fei YR, Fang L, Zheng HS, Chao-FengMu, Fan-ZhuLi, Zhang YS, Preparation of mixed monoterpenes edge activated PEGylated transfersomes to improve the in vivo transdermal delivery efficiency of sinomenine hydrochloride, International Journal of Pharmaceutics, 2017; 533(1):266-274.
26. Formulation Development and Evaluation of Ethosome of Stavudine Maurya SD, Prajapati SK, Gupta AK, Saxena GK, Dhakar RC, Indian J. Pharm. Educ. Res. 2010 Jan-Mar; 44(1):102-108.